NEW YORK, NY / ACCESSWIRE / July 19, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
XRAY Shareholders Click Here: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-submission-form?prid=29996&wire=1
OKTA Shareholders Click Here: https://www.zlk.com/pslra-1/okta-inc-loss-submission-form?prid=29996&wire=1
VRCA Shareholders Click Here: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=29996&wire=1
* ADDITIONAL INFORMATION BELOW *
Dentsply Sirona Inc. (NASDAQ:XRAY)
This lawsuit is on behalf of all persons or entities that purchased Dentsply’s common stock between June 9, 2021, and May 9, 2022.
Lead Plaintiff Deadline : August 1, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-submission-form?prid=29996&wire=1
According to the filed complaint, defendants orchestrated a scheme to inflate Dentsply’s revenue and earnings by manipulating the Company’s accounting for a distributor rebate program so that senior executives would be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the class period. As a result of defendants’ misrepresentations, Dentsply’s common stock traded at artificially inflated prices during the class period.
Okta, Inc. (NASDAQ:OKTA)
OKTA Lawsuit on behalf of: investors who purchased March 5, 2021 – March 22, 2022
Lead Plaintiff Deadline : July 19, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/okta-inc-loss-submission-form?prid=29996&wire=1
According to the filed complaint, during the class period, Okta, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Okta had inadequate cybersecurity controls; (ii) as a result, Okta’s systems were vulnerable to data breaches; (iii) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (iv) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (v) all the foregoing, once revealed, was likely to have a material negative impact on Okta’s business, financial condition, and reputation; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
VRCA Lawsuit on behalf of: investors who purchased May 28, 2021 – May 24, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/verrica-pharmaceuticals-inc-loss-submission-form?prid=29996&wire=1
According to the filed complaint, during the class period, Verrica Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/709084/CLASS-ACTION-UPDATE-for-XRAY-OKTA-and-VRCA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
